Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma

Abstract

AbstractBackgroundHepatic arterial infusion chemotherapy (HAIC) has demonstrated remarkable local therapeutic efficacy in treating patients with large unresectable hepatocellular carcinoma (HCC). Additionally, the combination of lenvatinib and programmed cell death protein‐1 (PD‐1) inhibitors has demonstrated promising antitumor effects in unresectable HCC. Therefore, we conducted a retrospective analysis to evaluate the efficacy and safety of combining HAIC with lenvatinib and PD‐1 inhibitors as a first‐line therapeutic approach in high‐burden HCC patients.MethodsWe conducted a retrospective analysis on patients diagnosed with high‐burden HCC who had major portal vein tumor thrombosis (Vp3 and Vp4) or tumor occupancy exceeding 50% of the liver. These patients received a first‐line treatment consisting of HAIC with a combination of 5‐fluorouracil, leucovorin, and oxaliplatin (FOLFOX), along with lenvatinib and PD‐1 inhibitors between November 2020 and June 2023. The primary endpoints of this study included progression‐free survival (PFS) and overall survival (OS), while the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and treatment‐related adverse events (TRAEs).ResultsNinety‐one patients were enrolled in this study, with a median PFS of 8.8 months (95% confidence interval [CI]: 5.75–11.78) and a median OS of 14.3 months (95% CI: 11.23–17.31). According to RECIST 1.1 criteria, the ORR was 52.7%, and DCR was 95.6%. According to the mRECIST criteria, the ORR was 72.5%, and the DCR was 96.5%. Among all patients, 86 (94.5%) experienced TRAEs, and there were no instances of treatment‐related deaths.ConclusionThe combination of HAIC‐FOLFOX with lenvatinib and PD‐1 inhibitors as a first‐line therapy has exhibited notable therapeutic efficacy and well‐tolerated adverse events among patients with high‐burden HCC.